Acute coronary syndromes: Should women receive less antithrombotic medication than men?

Heart

Volumn 90, Issue 4, 2004, Pages 363-366

  Danchin, N ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENDER; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 1642422842     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2002.003483     Document Type: Review

References (23)

1. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
2. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975;253:355-7.
3. Reading HW, Rosie R. Age and sex differences related to platelet aggregation. Biochem Soc Transcr 1980;8:180-1.
4. Michimata T, Imamura M, Mizuma H, et al. Sex and age differences in soluble guanylate cyclase activity in human platelets. Life Sci 1996;58:415-9.
5. Agarwal KC. Modulation of vasopressin actions on human platelets by plasma adenosine and theophylline: gender differences. J Cardiovasc Pharmacol 1993;21:1012-8.
6. Markham SM, Dubin NH, Rock JA. The effect of the menstrual cycle and of decompression stress on arachidonic acid-induced platelet aggregation and on intrinsic platelet thromboxane production in women compared with men. Am J Obstet Gynecol 1991;6:1821-9.
7. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GP IIb/IIIa activation. Thromb Haemost 1997;77:748-54.
8. Danielsen R, Onundarson PT, Thors H, et al. Activated and total coagulation factor VII and fibrinogen in coronary artery disease. Scand Cardiol J 1998;32:87-95.
9. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
10. Woodfield SL, Lundergad CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol 1997;29:35-42.
11. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-9.
12. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
13. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
14. Steinbuhl SR, Berger PB, Mann JT III, for the CREDO Investigators, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
15. Tardiff BE, Jennings LK, Harrington RA, for the PERIGEE Investigators, et al. Pharmacodynamcs and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001;104:405.
16. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis of EPIC, EPILOG, and EPISTENT trials. J Am Coll Cardiol 2000;36:381-6.
17. Fernandes LS, Tcheng JE, O'Shea JC, for the ESPRIT Investigators, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol 2002;40:1085-91.
18. Iakovou I, Dangas G, Mehran R, et al. Gender differences after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2002;89:976-9.
19. Sharaf BL, Pepine Q, Kerensky RA, et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot-phase data from the NHLBI-sponsored women's ischemia syndrome evaluation [WISE] study angiographic core laboratory). Am J Cardiol 2001;87:937-41.
20. Lagerqvist B, Säfström K, Stähle E, and the FRISC II Study Group Investigators, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? J Am Coll Cardiol 2001;38:41-8.
21. Roe MT, Harrington RA, Prosper DM, for the PURSUIT Trial Investigators, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. Circulation 2000;102:1101-6.
22. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2000;102:1093-100.
23. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The task force on the management of acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2002;23:1809-40.